# Bellco Capital

> Bellco Capital is a VC fund backing Biotechnology and Therapeutics. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Los Angeles, United States
- Total investments: 13
- Last investment: May 2024
- Lead investor: 0%
- Last updated: Aug 2026

Bellco Capital is a private equity firm based in Los Angeles, California.

## Contacts

5 contacts available for Bellco Capital. Shizune tracks 1 team members at Bellco Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bellco-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 46% |
| Therapeutics | 4 | 31% |
| Health Care | 3 | 23% |
| Medical | 2 | 15% |
| Baby | 1 | 8% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 23% |
| Private Equity | 3 | 23% |
| Series B | 2 | 15% |
| Seed | 1 | 8% |
| Series C | 1 | 8% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 54% |
| The Netherlands | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Arie Belldegrun | Co-Founder and Chairman | 5 | https://shizune.co/investors/profile/arie-belldegrun |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M |  | May 13, 2024 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M | Series C | May 13, 2024 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M | Series C | May 13, 2024 |  |
| Breakthrough Properties | Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. |  | Private Equity | Jan 01, 2023 |  |
| First Media | First Media is dedicated to inspiring the do-it-all millennial woman with four media properties focused on clever ways to live better. Its growing communities of 115 million fans worldwide play with their food with So Yummy, life hack with Blossom, make beauty a breeze with Blusher and watch baby blossom on BabyFirst. Online, fans generate 1.5billion views and 50+ million engagements each month. |  | Private Equity | Jan 01, 2022 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $90M | Series B | Jul 26, 2021 |  |
| IconOVir Bio | IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. | $77M | Series A | Jan 05, 2021 |  |
| Cell Design Labs | Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power,precision, safety and durability |  | Private Equity | Jan 01, 2021 |  |
| Dewpoint Therapeutics | Dewpoint Therapeutics is a biotech company which develop a drug platform that targets biomolecular condensates. | $77M | Series B | Sep 29, 2020 |  |
| Neogene Therapeutics | Neogene Therapeutics provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens. The company is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.Neogene's platform allows for theisolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The company’s proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale. | $110M | Series A | Sep 14, 2020 |  |

10 of 13 investments shown.

## Co-investors
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 9 deals together
- [Two River](https://shizune.co/investors/profile/two-river) — VC Fund, 8 deals together
- [D1 Capital Partners](https://shizune.co/investors/profile/d1-capital-partners) — VC Fund, 6 deals together
- [OCV](https://shizune.co/investors/profile/ocv) — VC Fund, 6 deals together
- [Red Sea Ventures](https://shizune.co/investors/profile/red-sea-venture-partners) — VC Fund, 6 deals together
- [AccelFoods](https://shizune.co/investors/profile/accelfoods) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bellco Capital invest in?

Bellco Capital invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Private Equity stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bellco Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bellco Capital?

The team at Bellco Capital includes Arie Belldegrun (Co-Founder and Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co